Drugs / clonal fetal MSCs
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT03123458 | Jan 2025 → Dec 2028 expected | immune system disorder | Shenzhen Geno-Immune Medical Institute | Enrolling by invitation | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT07477600 | Mar 2026 → Mar 2029 expected | chronic obstructive pulmonary disease | Shenzhen Geno-Immune Medical Institute | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | clonal fetal MSCs | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03123458 ↗ |
| Known as | cfMSCs | “Fetal tissue-derived clonal MSCs (cfMSCs) have extended expansion potential and express rich levels of various growth factors, and thus can achieve quality consistency.” NCT03123458 ↗1“Clonal fetal mesenchymal stem cells (cfMSCs) are isolated and clonally characterized fetal tissue-derived MSCs” NCT07477600 ↗ |
| Modality | Cell therapy | “infusion of the third party fully-characterized clonally derived fetal MSCs (cfMSCs)” NCT03123458 ↗ |
| Route | Other | “infusion of fully characterized clonally derived fetal mesenchymal stem cells (cfMSCs)” NCT07477600 ↗ |